Form 6K Cellectis For: 11 June
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis SA (CLLS)
Cellectis SA stock price live, this page displays NASDAQ CLLS stock exchange data. View the CLLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectis SA real time stock price chart below.
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 3.300.
What Is the Stock Symbol for Cellectis SA?
The stock ticker symbol for Cellectis SA is CLLS.
Is CLLS the Same as $CLLS?
$CLLS is a common way to refer to the Cellectis SA ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Cellectis SA share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 3.300.
What Is the Stock Symbol for Cellectis SA?
The stock ticker symbol for Cellectis SA is CLLS.
Is CLLS the Same as $CLLS?
$CLLS is a common way to refer to the Cellectis SA ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Cellectis SA share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
3.300
0.000(0.00%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.300
3.300
52 wk Range
1.558
5.480
CLLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.3003.300
52 wk Range
1.5585.480
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
7.600
Upside
+130.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Cellectis stock rises on FDA therapy designation
- Investing.com
- Cellectis receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Cellectis For: 9 June
- Investing.com
- Form 6K Cellectis For: 11 June
- Investing.com
- Cellectis stock rises on FDA therapy designation
- Investing.com
- Form 6K Cellectis For: 9 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.600
(+130.30% Upside)
Cellectis SA SWOT Analysis
Manufacturing Edge | Discover how Cellectis's off-the-shelf allogeneic approach addresses critical limitations in traditional CAR-T therapies, potentially enabling faster patient access |
Regulatory Roadmap | The company targets a pivotal Phase 2 interim analysis in Q4 2026, with a Biologics License Application filing anticipated in 2028 for market entry |
Analyst Outlook | Analysts maintain price targets of $8.00, reflecting confidence in the company's gene-editing technology and pipeline advancement toward commercialization |
Clinical Breakthrough | Cellectis achieved an 88% overall response rate in relapsed/refractory non-Hodgkin lymphoma, demonstrating the potential of its allogeneic CAR-T platform |
Cellectis SA Earnings Call Summary for Q4/2025
- Cellectis Q4 2025 EPS of -$0.19 beat forecast of -$0.2948 by 35.55%; revenue of $17.1M exceeded $10.02M estimate by 70.66%, driving 2% stock gain.
- Cash position stands at $211M as of Dec 31, 2025, with runway extending through H2 2027; FY2026 quarterly EPS guidance set at -$0.02.
- Internal manufacturing capabilities validated with 68% overall response rate, significantly outperforming external production in lasme-cel and eti-cel programs.
- Key data readouts for lasme-cel and eti-cel programs expected in 2026; company expanding Paris and Raleigh facilities to support growth.
- Stock rose to $3.55 in premarket trading, within 52-week range of $1.10-$5.48; faces risks from regulatory hurdles and CAR-T market competition.
Last Updated: 03/20/2026, 08:59 AM
Read Full TranscriptEarnings
Latest Release
May 11, 2026
EPS / Forecast
-0.18 / -0.26
Revenue / Forecast
12.02M / 13.02M
Compare CLLS to Peers and Sector
Metrics to compare | CLLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −2.0x | −0.4x | |
PEG Ratio | 0.44 | −0.10 | 0.00 | |
Price / Book | 4.0x | 1.5x | 2.6x | |
Price / LTM Sales | 3.2x | 4.5x | 3.0x | |
Upside (Analyst Target) | 142.4% | 108.5% | 49.1% | |
Fair Value Upside | Unlock | 2.0% | 6.3% | Unlock |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cellectis (CLLS) Stock Price Today?
The Cellectis stock price today is 3.300 USD.
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is "CLLS."
What Is the Cellectis Market Cap?
As of today, Cellectis market cap is 236.260M USD.
What Is Cellectis's Earnings Per Share (TTM)?
The Cellectis EPS (TTM) is -0.670.
When Is the Next Cellectis Earnings Date?
Cellectis will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is CLLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Cellectis Stock Split?
Cellectis has split 0 times.
How Many Employees Does Cellectis Have?
Cellectis has 227 employees.
What is the current trading status of Cellectis (CLLS)?
As of Jul 06, 2026, Cellectis (CLLS) is trading at a price of 3.300 USD, with a previous close of 3.300 USD. The stock has fluctuated within a day range of 3.300 USD to 3.300 USD, while its 52-week range spans from 1.558 USD to 5.480 USD.
What Is Cellectis (CLLS) Price Target According to Analysts?
The average 12-month price target for Cellectis is 7.600 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +130.30% Upside potential.
What Is the CLLS Premarket Price?
CLLS's last pre-market stock price is 3.310 USD. The pre-market share volume is 16.000, and the stock has decreased by 0.010, or 0.300%.
What Is the CLLS After Hours Price?
CLLS's last after hours stock price is 3.268 USD, the stock has decreased by -0.032, or -0.960%.
Industry Spotlight
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.